List of ORNs
| Suite . | ORN ID . | Backbone . | Modification . | Sequence . |
|---|---|---|---|---|
| pUC | pUC | PD | -- | U-C-U-C-U-C-U-C-U-C-U-C-U-C-U-C-U-C-U-C |
| pUC-O | PD | OMe | U-mC-U-mC-U-mC-U-mC-U-mC-U-mC-U-mC-U-mC-U-mC-U-C | |
| pUC-F | PD | F | U-fC-U-fC-U-fC-U-fC-U-fC-U-fC-U-fC-U-fC-U-fC-U-C | |
| pUC-U2′O | PD | OMe | mU-C-mU-C-mU-C-mU-C-mU-C-mU-C-mU-C-mU-C-mU-C-mU-C-U | |
| pUC-U2′F | PD | F | fU-C-fU-C-fU-C-fU-C-fU-C-fU-C-fU-C-fU-C-fU-C-fU-C | |
| pUC-PS | PS | -- | U*C*U*C*U*C*U*C*U*C*U*C*U*C*U*C*U*C*U*C | |
| pU2C | pUUC | PD | -- | C-C-U-U-C-U-U-C-U-U-C-U-U-C-U-U-C-U-U-C |
| pUUC-F | PD | F | C-C-fU-U-C-fU-U-C-fU-U-C-fU-U-C-fU-U-C-fU-U-C | |
| pUUC-O | PD | OMe | C-C-mU-U-C-mU-U-C-mU-U-C-mU-U-C-mU-U-C-mU-U-C | |
| pUUC-PS | PS | -- | C*C*U*U*C*U*U*C*U*U*C*U*U*C*U*U*C*U*U*C | |
| U4.G | U4.G-PS | PS | -- | C*C*G*A*G*C*C*G*C*U*U*U*U*C*C*C |
| U4.G-PS-OO | PS | OMe-OMe | C*C*G*A*G*C*C*G*C*mU-U*mU-U*C*C*C | |
| U4.G-PS-FF | PS | F-F | C*C*G*A*G*C*C*G*C*fU-U*fU-U*C*C*C | |
| U4.G-PS-OF | PS | OMe-F | C*C*G*A*G*C*C*G*C*mU-U*fU-U*C*C*C | |
| U4.G-PS-FO | PS | F-OMe | C*C*G*A*G*C*C*G*C*fU-U*mU-U*C*C*C | |
| U4.G-PD | PD | -- | C-C-G-A-G-C-C-G-C-U-U-U-U-C-C-C | |
| U4.G-PD-OO | PD | OMe-OMe | C-C-G-A-G-C-C-G-C-mU-U-mU-U-C-C-C | |
| U4.G-PD-FF | PD | F-F | C-C-G-A-G-C-C-G-C-fU-U-fU-U-C-C-C | |
| U4.G-PD-OF | PD | OMe-F | C-C-G-A-G-C-C-G-C-mU-U-fU-U-C-C-C | |
| U4.G-PD-FO | PD | F-OMe | C-C-G-A-G-C-C-G-C-fU-U-mU-U-C-C-C | |
| Control | pUUG | PD | -- | G-G-U-U-G-U-U-G-U-U-G-U-U-G-U-U-G-U-U-G |
| Suite . | ORN ID . | Backbone . | Modification . | Sequence . |
|---|---|---|---|---|
| pUC | pUC | PD | -- | U-C-U-C-U-C-U-C-U-C-U-C-U-C-U-C-U-C-U-C |
| pUC-O | PD | OMe | U-mC-U-mC-U-mC-U-mC-U-mC-U-mC-U-mC-U-mC-U-mC-U-C | |
| pUC-F | PD | F | U-fC-U-fC-U-fC-U-fC-U-fC-U-fC-U-fC-U-fC-U-fC-U-C | |
| pUC-U2′O | PD | OMe | mU-C-mU-C-mU-C-mU-C-mU-C-mU-C-mU-C-mU-C-mU-C-mU-C-U | |
| pUC-U2′F | PD | F | fU-C-fU-C-fU-C-fU-C-fU-C-fU-C-fU-C-fU-C-fU-C-fU-C | |
| pUC-PS | PS | -- | U*C*U*C*U*C*U*C*U*C*U*C*U*C*U*C*U*C*U*C | |
| pU2C | pUUC | PD | -- | C-C-U-U-C-U-U-C-U-U-C-U-U-C-U-U-C-U-U-C |
| pUUC-F | PD | F | C-C-fU-U-C-fU-U-C-fU-U-C-fU-U-C-fU-U-C-fU-U-C | |
| pUUC-O | PD | OMe | C-C-mU-U-C-mU-U-C-mU-U-C-mU-U-C-mU-U-C-mU-U-C | |
| pUUC-PS | PS | -- | C*C*U*U*C*U*U*C*U*U*C*U*U*C*U*U*C*U*U*C | |
| U4.G | U4.G-PS | PS | -- | C*C*G*A*G*C*C*G*C*U*U*U*U*C*C*C |
| U4.G-PS-OO | PS | OMe-OMe | C*C*G*A*G*C*C*G*C*mU-U*mU-U*C*C*C | |
| U4.G-PS-FF | PS | F-F | C*C*G*A*G*C*C*G*C*fU-U*fU-U*C*C*C | |
| U4.G-PS-OF | PS | OMe-F | C*C*G*A*G*C*C*G*C*mU-U*fU-U*C*C*C | |
| U4.G-PS-FO | PS | F-OMe | C*C*G*A*G*C*C*G*C*fU-U*mU-U*C*C*C | |
| U4.G-PD | PD | -- | C-C-G-A-G-C-C-G-C-U-U-U-U-C-C-C | |
| U4.G-PD-OO | PD | OMe-OMe | C-C-G-A-G-C-C-G-C-mU-U-mU-U-C-C-C | |
| U4.G-PD-FF | PD | F-F | C-C-G-A-G-C-C-G-C-fU-U-fU-U-C-C-C | |
| U4.G-PD-OF | PD | OMe-F | C-C-G-A-G-C-C-G-C-mU-U-fU-U-C-C-C | |
| U4.G-PD-FO | PD | F-OMe | C-C-G-A-G-C-C-G-C-fU-U-mU-U-C-C-C | |
| Control | pUUG | PD | -- | G-G-U-U-G-U-U-G-U-U-G-U-U-G-U-U-G-U-U-G |
ORNs are listed by foundation sequence. Foundation sequence pUC (5′-UCUCUCUCUCUCUCUCUCUC-3′) and foundation sequence pUUC (5′-CCUUCUUCUUCUUCUUCUUC-3′) were both previously shown to have TLR7 activity when codelivered with guanosine (Zhang et al., 2018). For pUC, we engineered 2′ modifications on the cytidines to maintain an unmodified U2 in any resulting CUC products, or on the uridines to assess site-specificity. For pUUC, we included 2′ modifications on U1 in the UUC motif to inhibit the generation of monomeric uridine. In addition, we engineered both sequences with a PS backbone. For foundation sequence U4.G (5′-CCGAGCCGCUUUUCCC-3′; Forsbach et al., 2008), we introduced 2′ modifications on U1 and U3. We also created 2′ modified versions with a PS backbone throughout. Within the sequences, “-” indicates the standard PD backbone, and “*” indicates the PS backbone. Bold font indicates the modified nucleotides, where “f_” is a 2′fluoro (“F”) and “m_” is a 2′O-methyl (“OMe”) modification.